Resveratrol as MDR reversion molecule in breast cancer: An overview

Food and Chemical Toxicology

Volumn 103, Issue , 2017, Pages 223-232

  Alamolhodaei, Nafiseh Sadat ^a   Tsatsakis, Aristidis M ^b   Ramezani, Mohammad ^c   Hayes, A Wallace ^d   Karimi, Gholamreza ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF CRETE   (Greece)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Breast cancer; Multidrug resistance; Phytoestrogens; Resveratrol

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450; DACTINOMYCIN; DEATH RECEPTOR; DNA; DOXORUBICIN; EPOXIDE HYDROLASE; ESTRADIOL; ESTROGEN RECEPTOR; FERULIC ACID; FLAVONOID; FUMARIC ACID; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HORMONE RECEPTOR; MELPHALAN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; POLYPHENOL DERIVATIVE; PROTEIN P53; QUERCETIN; RESVERATROL; ANTINEOPLASTIC AGENT; PHYTOESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CELL CYCLE REGULATION; DNA REPAIR; DRUG BINDING SITE; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; HORMONE INHIBITION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW; STRUCTURE ANALYSIS; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG INACTIVATION; DRUG RESISTANCE; FEMALE; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; DNA REPAIR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INACTIVATION, METABOLIC; PHYTOESTROGENS; STILBENES;

EID: 85015412335     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2017.03.024     Document Type: Review

References (113)

1. Abdal Dayem, A., Choi, H.Y., Yang, G.-M., Kim, K., Saha, S.K., Cho, S.-G., The anti-cancer effect of polyphenols against breast cancer and cancer stem cells: molcular mechanisms. Nutr, 8, 2016, 581.
2. Adhami, V.M., Afaq, F., Ahmad, N., Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem. Biophys. Res. Commun 288 (2001), 579–585.
3. Ahmad, N., Adhami, V.M., Afaq, F., Feyes, D.K., Mukhtar, H., Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin. Cancer. Res. 7 (2001), 1466–1473.
4. Alkhalaf, M., Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation. Eur. J. Cancer. Prev 16 (2007), 334–341.
5. Al-Abd, A.M., Mahmoud, A.M., El-Sherbiny, G.A., El-Moselhy, M.A., Nofal, S.M., El-Latif, H.A., El-Eraky, W., El-Shemy, H., Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumor cell lines in vitro. Cell. Prolif. 44 (2011), 591–601.
6. Alamolhodaei, N.S., Behravan, J., Mosaffa, F., Karimi, G., Mir 221/222 as new players in tamoxifen resistance. Curr. Pharm. Des. 22:46 (2016), 6946–6955.
7. Androutsopoulos, V.P., Ruparelia, K.C., Papakyriakou, A., Filippakis, H., Tsatsakis, A.M., Spandidos, D.A., Anticancer effects of the metabolic products of the resveratrol analogue, DMU-212: structural requirements for potency. Eur. J. Med. Chem. 46:6 (2011), 2586–2595.
8. Apostolou, A., Stagos, D., Galitsiou, E., Spyrou, A., Haroutounian, S., Portesis, N., Trizoglou, I., Hayes, A.W., Tsatsakis, A.M., Kouretas, D., Assessment of polyphenolic content, antioxidant activity, protection against ROS-induced DNA damage and anticancer activity of Vitis vinifera stem extracts. Food Chem. Toxicol. 61 (2013), 60–68.
9. Androutsopoulos, V.P., Tsatsakis, A.M., Benzo[a]pyrene sensitizes MCF7 breast cancer cells to induction of G1 arrest by the natural flavonoid eupatorin-5-methyl ether, via activation of cell signaling proteins and CYP1-mediated metabolism. Toxicol. Lett. 230:2 (2014), 304–313.
10. Androutsopoulos, V.P., Ruparelia, K., Arroo, R.R., Tsatsakis, A.M., Spandidos, D.A., CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicol 264:3 (2009), 162–170.
11. Azizi, E., Namazi, A., Kaabinejadian, S., Fouladdel, S., Rezaei, P., Ramezani, M., Molecular analysis of MEN1 expression in MCF7, T47D and MDA-MB 468 breast cancer cell lines treated with adriamycin using RT-PCR and immunocytochemistry. Daru, 2010, 18.
12. Bartolacci, C., Andreani, C., Amici, A., Marchini, C., Walking a tightrope: a perspective of resveratrol effects on breast cancer. Curr. Protein Pept. Sci., 2017.
13. Basly, J.P., Marre-Fournier, F., Le Bail, J.C., Habrioux, G., Chulia, A.J., Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life. Sci. 66 (2000), 769–777.
14. Baur, J.A., Sinclair, D.A., Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug. Discov 5 (2006), 493–506.
15. Bai, Y., Yang, H., Zhang, G., Hu, L., Lei, Y., Qin, Y., Yang, Y., Wang, Q., Li, R., Mao, Q., Inhibitory effects of resveratrol on the adhesion, migration and invasion of human bladder cancer cells. Mol. Med. Rep. 15 (2016), 885–889.
16. Bernhard, D., Tinhofer, I., Tonko, M., Hubl, H., Ausserlechner, M.J., Greil, R., Kofler, R., Csordas, A., Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. Cell.death. Differ. 7 (2000), 834–842.
17. Bhat, K.P., Lantvit, D., Christov, K., Mehta, R.G., Moon, R.C., Pezzuto, J.M., Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer. Res. 61 (2001), 7456–7463.
18. Borska, S., Pedziwiatr, M., Danielewicz, M., Nowinska, K., Pula, B., Drag-Zalesinska, M., Olbromski, M., Gomulkiewicz, A., Dziegiel, P., Classical and atypical resistance of cancer cells as a target for resveratrol. Oncol. Reps 36 (2016), 1562–1568.
19. Brown, C.M., Reisfeld, B., Mayeno, A.N., Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug. Metab. Rev. 40 (2008), 1–100.
20. Brownson, D.M., Azios, N.G., Fuqua, B.K., Dharmawardhane, S.F., Mabry, T.J., Flavonoid effects relevant to cancer. J. Nutr. 132 (2002), 3482–3489.
21. Cao, Z., Li, Y., Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur. J. Pharmacol. 489 (2004), 39–48.
22. Carter, L.G., D'Orazio, J.A., Pearson, K.J., Resveratrol and cancer: focus on in vivo evidence. Endocr. Relat. Cancer 21 (2014), 209–225.
23. Casper, R.F., Quesne, M., Rogers, I.M., Shirota, T., Jolivet, A., Milgrom, E., Savouret, J.-F., Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol. Pharmacol. 56 (1999), 784–790.
24. Castoria, G., Migliaccio, A., Bilancio, A., Di Domenico, M., De Falco, A., Lombardi, M., Fiorentino, R., Varricchio, L., Barone, M.V., Auricchio, F., PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO. J. 20 (2002), 6050–6059.
25. Casanova, F., Quarti, J., da Costa, D.C.F., Ramos, C.A., da Silva, J.L., Fialho, E., Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest. J. cell.Biochem. 113 (2012), 2586–2596.
26. Clement, M.V., Hirpara, J.L., Chawdhury, S.H., Pervaiz, S., Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92 (1998), 996–1002.
27. Chimento, A., Sirianni, R., Saturnino, C., Caruso, A., Sinicropi, M.S., Pezzi, V., Resveratrol and its analogs as antitumoral agents for breast cancer treatment. Min. Rev. Med. Chem. 16 (2016), 699–709.
28. Chen, F.P., Chien, M.H., Phytoestrogens induce apoptosis through a mitochondria/caspase pathway in human breast cancer cells. Climacteric 17 (2014), 385–392.
29. Chow, H.H., Garland, L.L., Heckman-Stoddard, B.M., Hsu, C.H., Butler, V.D., Cordova, C.A., Chew, W.M., Cornelison, T.L., A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones. J. Transl. Med., 12, 2014, 223.
30. Ciolino, H.P., Yeh, G.C., Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol. Pharmacol. 56 (1999), 760–767.
31. Cooray, H.C., Janvilisri, T., van Veen, H.W., Hladky, S.B., Barrand, M.A., Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun. 317 (2004), 269–275.
32. Costa, C., Ozcagli, E., Gangemi, S., Schembri, F., Giambò, F., Androutsopoulos, V., Tsatsakis, A., Fenga, C., Molecular biomarkers of oxidative stress and role of dietary factors in gasoline station attendants. Food Chem. Toxicol. 90 (2016), 30–35.
33. Danz, E.D., Skramsted, J., Henry, N., Bennett, J.A., Keller, R.S., Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free. Radic. Biol. Med. 46 (2009), 1589–1597.
34. Dixon, R.A., Phytoestrogens. Annu. Rev. Plant. Biol. 55 (2004), 225–261.
35. Dorrie, J., Gerauer, H., Wachter, Y., Zunino, S.J., Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer. Res. 61 (2001), 4731–4739.
36. Du, C., Dong, M.H., Ren, Y.J., Jin, L., Xu, C., Design, synthesis and antibreast cancer MCF-7 cells biological evaluation ofheterocyclic analogs of resveratrol. J. Asian. Nat. Prod. Res. 3 (2016), 1–13.
37. El-Mowafy, A.M., Alkhalaf, M., Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogen 24 (2003), 869–873.
38. Fas, S., Fritzsching, B., Suri-Payer, E., Kramme, r.P., Death receptor signaling and its function in the immune system. Elkon, K.B., (eds.) Apoptosis and its Relevance to Autoimmunity, 2006, Karger. Publishers, Germany, 1–17.
39. Fenga, C., Costa, C., Caruso, E., Raffa, L., Alibrando, C., Hangemi, S., Docea, A., Tsatsakis, A., Current evidence on the protective effect of dietary polyphenols on breast cancer. Farmacia 64:1 (2016), 1–12.
40. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int. J. Cancer 136 (2015), 359–386.
41. Filomeni, G., Graziani, I., Rotilio, G., Ciriolo, M., trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes. Nut 2 (2007), 295–305.
42. Fukui, M., Yamabe, N., Zhu, B.T., Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur. J. Cancer 46 (2010), 1882–1891.
43. Fulda, S., Debatin, K.M., Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 23 (2004), 6702–6711.
44. Ganry, O., Phytoestrogen and breast cancer prevention. Eur. J. Cancer. Prev. 11 (2002), 519–522.
45. Garofalo, M., Croce, C.M., MicroRNAs as therapeutic targets in chemoresistance. Drug. resist. updat. 16 (2013), 47–59.
46. Gatz, S.A., Wiesmülle, r.L., Take a break—resveratrol in action on DNA. Carcinogene 29 (2008), 321–332.
47. Gatouillat, G., Ebalasse, E., Joseph-Pietras, B., Morjani, H., Madoulet, C., Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16melanoma. J. Cell.Biochem. 110 (2010), 893–902.
48. Goutzourelas, N., Stagos, D., Spanidis, Y., Liosi, M., Apostolou, A., Priftis, A., Haroutounian, S., Spandidos, D.A., Tsatsakis, A.M., Kouretas, D., Polyphenolic composition of grape stem extracts affects antioxidant activity in endothelial and muscle cells. Mol. Med. Rep. 12:4 (2015), 5846–5856.
49. Hashemzaei, M., Karami, S.p., Delaramifar, A., Sheidary, A., Tabrizian, K., Rezaee, R., Shahsavand, S., Arsene, A.L., Tsatsakis, A.M., Mohammad, S., Anticancer effects of co-administration of daunorubicin and resveratrol in Molt-4, U266 B1 and Raji cell lines. Farmacia 64 (2016), 36–42.
50. Hashemzaei, M., Barani, A.K., Iranshahi, M., Rezaee, R., Tsarouhas, K., Tsatsakis, A.M., Wilks, M.F., Tabrizian, K., Effects of resveratrol on carbon monoxide-induced cardiotoxicity in rats. Environ. Toxicol. Pharmacol. 46 (2016), 110–115.
51. Haider, U.G., Sorescu, D., Griendling, K.K., Vollmar, A.M., Dirsch, V.M., Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells. Mol. Pharmacol. 63 (2003), 925–932.
52. Hee Choi, Y., Yu, A.-M., ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr. Pharm. Des. 20 (2014), 793–807.
53. Huang, Z., Huang, Q., Ji, L., Wang, Y., Qi, X., Liu, L., LIU, Z., LU, L., Epigenetic regulation of active Chinese herbal components for cancer prevention and treatment: a follow-up review. Pharmacol. Res. 114 (2016), 1–12.
54. Huang, F., Wu, X.-N., Chen, J., Wang, W.-X., Lu, Z.F., Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells. Exp. Ther. Med. 7 (2014), 1611–1616.
55. Huang, F., Huang, Z.J., Chen, J., Wang, J.L., Studies of several polyphenolses on multidrug resistance to human breast carcinoma MCF-7/ADM cell. J. Pract. Oncol 24 (2009), 121–123.
56. Izquierdo-Torres, E., Rodríguez, G., Meneses-Morales, I., Zarain-Herzberg, A., ATP2A3 gene as an important player for resveratrol anticancer activity in breast cancer cells. Mol. Carcinog., 2017.
57. Joe, A.K., Liu, H., Suzui, M., Vural, M.E., Xiao, D., Weinstein, I.B., Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin. Cancer. Res. 8 (2002), 893–903.
58. Juan, M.E., Alfaras, I., Planas, J.M., Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol. Res. 65 (2012), 584–591.
59. Karimi, G., Vahabzadeh, M., Lari, P., Rashedinia, M., Moshiri, M., “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran. J. Basic. Med. Sci. 14:4 (2011), 308–317.
60. Kim, T.H., Shin, Y.J., Won, A.J., Lee, B.M., Choi, W.S., Jung, J.H., Chung, H.Y., Kim, H.S., Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochimica Biophysica Acta (BBA)-General Subj. 1840 (2014), 615–625.
61. Kuiper, G., Lemmen, J., Carlsson, B., Corton, J., Safe, S., van der Saag, P., Van Der Burg, B., Gustafsson, J.-A.K., Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinol 139 (1998), 4252–4263.
62. Laux, M.T., Aregullin, M., Berry, J.P., Flanders, J.A., Rodriguez, E., Identification of a p53-dependent pathway in the induction of apoptosis in human breast cancer cells by the natural product, resveratrol. J. Altern. Complement. Med. 10 (2004), 235–239.
63. Levenson, A.S., Gehm, B.D., Pearce, S.T., Horiguchi, J., Simons, L.A., Ward, J.E. III, Jameson, J.L., Jordan, V.C., Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int. J. Cancer 104 (2003), 587–596.
64. Levi, F., Pasche, C., Lucchini, F., Ghidoni, R., Ferraroni, M., Vecchia, La, Resveratrol and breast cancer risk. Eur. J. Cancer. Prev. 14 (2005), 139–142.
65. Licznerska, B., Szaefer, H., Wierzchowski, M., Sobierajska, H., Baer-Dubowska, W., Resveratrol and itsmethoxy derivatives modulate the expression of estrogen metabolism enzymes in breast epithelial cells by AhR down-regulation. Mol. Cell.Biochem. 425 (2017), 169–179.
66. Liu, I.H., Ford, J.M., Kunz, P.L., DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Cancer. Treat. Rev. 44 (2016), 1–9.
67. Li, W., Zhang, H., Assaraf, Y.G., Zhao, K., Xu, X., Xie, J., Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug. resist. updat. 27 (2016), 14–29.
68. Li, Z., Cui, J., Yu, Q., Wu, X., Pan, A., Li, L., Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers. Am. J. Transl. Res., 8, 2016, 142.
69. Mahdizadeh, S., Karimi, G., Behravan, J., Arabzadeh, S., Lage, H., Kalalinia, F., Crocin suppresses multidrug resistance in MRP overexpressing ovarian cancer cell line. DARU J. Pharm. Sci., 24, 2016, 17.
70. Margină, D., Ilie, M., Grădinaru, D., Androutsopoulos, V.P., Kouretas, D., Tsatsakis, A.M., Natural products-friends or foes?. Toxicol. Lett. 236:3 (2015), 154–167.
71. Miltonprabu, S., Nazimabashir, Manoharan, V., Hepatoprotective effect of grape seed proanthocyanidins on Cadmium-induced hepatic injury in rats: possible involvement of mitochondrial dysfunction, inflammation and apoptosis. Toxicol. Rep. 3 (2016), 63–77.
72. Mondal, A., Bennett, L.L., Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARPcleavage. Biomed. Pharmacother. 84 (2016), 1906–1914.
73. Nabekura, T., Kamiyama, S., Kitagawa, S., Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun. 327 (2005), 866–870.
74. Nakagawa, H., Kiyozuka, Y., Uemura, Y., Senzaki, H., Shikata, N., Hioki, K., Tsubura, A., Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J. Cancer. Res. Clin. Oncol 127 (2001), 258–264.
75. Nguyen, T.H., Mustafa, F.B., Pervaiz, S., Ng, F.S., Lim, L.H., ERK1/2 activation is required for resveratrol-induced apoptosis in MDA-MB-231 cells. Int. J. Oncol. 33 (2008), 81–92.
76. Nourbakhsh, M., Jaafari, M.R., Lage, H., Abnous, K., Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran. J. Basic. Med. Sci., 18, 2015, 385.
77. Osman, A.M., Al-Harthi, S., AlArabi, O., Elshal, M., Ramadan, W., Alaama, M., Chemosensetizing and cardiopro- tective effects of resveratrol in doxorubicin-treated animals. Cancer. Cell. Int., 13, 2013, 52.
78. Park, M.A., Hwang, K.A., Choi, K.C., Diverse animal models to examine potential role(s) and mechanism of endocrine disrupting chemicals on the tumor progression and prevention: do they have tumorigenic or anti-tumorigenic property. Lab. Anim. Res. 27 (2011), 265–273.
79. Patel, K.R., Brown, V.A., Jones, D.J., Britton, R.G., Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer. Res. 70 (2010), 7392–7399.
80. Pavan, A.R., Silva, G.D.B.d., Jornada, D.H., Chiba, D.E., Fernandes, G.F.d.S., Man Chin, C., Unraveling the anticancer effect of curcumin and resveratrol. Nutrients, 8, 2016, 628.
81. Peña-Diaz, J., Rasmussen, L.J., Approaches to diagnose DNA mismatch repair gene defects in cancer. DNA. Repair 38 (2016), 147–154.
82. Piccinato, C.A., Neme, R.M., Torres, N., Sanches, L.R., Derogis, P.B.M.C., Brudniewski, H.F., Increased expression of CYP1A1 and CYP1B1 in ovarian/peritoneal endometriotic lesions. Reproduction 151 (2016), 683–692.
83. Pilsakova, L., Riecansky, I., Jagla, F., The physiological actions of isoflavone phytoestrogens. Physiol. Res. 59 (2010), 651–664.
84. Pozo-Guisado, E., Alvarez-Barrientos, A., Mulero-Navarro, S., Santiago-Josefat, B., Fernandez-Salguero, P.M., The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem. Pharmacol. 64 (2002), 1375–1386.
85. Ragione, F.D., Cucciolla, V., Borriello, A., Pietra, V.D., Racioppi, L., Soldati, G., Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem. Biophys. Res. Commun. 250 (1998), 53–58.
86. Rai, G., Mishra, S., Suman, S., Shukla, Y., Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: a mechanistic insight. Phytomed 23 (2016), 233–242.
87. Rauf, A., Imran, M., Butt, M.S., Nadeem, M., Peters, D.G., Mubarak, M.S., Resveratrol as an anticancer agent: a review. Crit. Rev. Food Sci. Nutr., 2016.
88. Razavi-Azarkhiavi, K., Iranshahy, M., Sahebkar, A., Shirani, K., Karimi, G., The protective role of phenolic compounds against doxorubicin-induced cardiotoxicity: a comprehensive review. Nut. Cancer 68 (2016), 892–917.
89. Razavi, B.M., Karimi, G., Protective effect of silymarin against chemical-induced cardiotoxicity. Iran. J. Basic. Med. Sci., 19(9), 2016, 916.
90. Regev-Shoshani, G., Shoseyov, O., Bilkis, I., Kerem, Z., Glycosylation of resveratrol protects it from enzymic oxidation. Biochem. J. 374 (2003), 157–163.
91. Rieder, S.A., Nagarkatti, P., Nagarkatti, M., Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B- induced lung injury. Br. J. Pharmacol. 167 (2012), 1244–1258.
92. Sarkaria, J.N., Kitange, G.J., James, C.D., Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer. Res. 14 (2008), 2900–2908.
93. Sareen, D., Darjatmoko, S.R., Albert, D.M., Polans, A.S., Mitochondria, calcium,and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. Mol. Pharmacol. 72 (2007), 1466–1475.
94. Scarlatti, F., Sala, G., Somenzi, G., Signorelli, P., Sacchi, N., Ghidoni, R., Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. Faseb. J. 17 (2003), 2339–2341.
95. Shankar, S., Singh, G., Srivastava, R.K., Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front. Biosci. 12 (2006), 4839–4854.
96. Singh, B., Shoulson, R., Chatterjee, A., Ronghe, A., Bhat, N.K., Dim, D.C., Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways. Carcinogen 35 (2014), 1872–1880.
97. Singh, C.K., Ndiaye, M.A., Ahmad, N., Resveratrol and cancer: challenges for clinical translation. Biochim. Biophys. Acta 1852 (2015), 1178–1185.
98. Sinha, D., Sarkar, N., Biswas, J., Bishayee, A., Resveratrol for breast cancer prevention and therapy: preclinical evidence and molecular mechanisms. Sem. Cancer. Boil. Elsevier 40–41 (2016), 209–232.
99. Singh, N., Nigam, M., Ranjan, V., Sharma, R., Balapure, A.K., Rath, S.K., Caspase mediated enhanced apoptotic action of cyclophosphamide-and resveratrol-treated MCF-7 cells. J. Pharmacol. Sci. 109 (2009), 473–485.
100. Smoliga, J.M., Baur, J.A., Hausenbla, s.H.A., Resveratrol and health–a comprehensive review of human clinical trials. Mol. Nutr. Food. Res. 55 (2011), 1129–1141.
101. Sjöstedt, N., Holvikari, K., Tammela, P.i., Kidron, H., Inhibition of breast cancer resistance protein and multidrug resistance associated protein 2 by natural compounds and their derivatives. Mol. Pharm. 14 (2016), 135–146.
102. Staaf, J., Ringner, M., Making breast cancer molecular subtypes robust?. J. Natl. Cancer. Inst., 107, 2015, 386.
103. Stagos, D., Amoutzias, G.D., Matakos, A., Spyrou, A., Tsatsakis, A.M., Kouretas, D., Chemoprevention of liver cancer by plant polyphenols. Food Chem. Toxicol. 50:6 (2012), 2155–2170.
104. Stagos, D., Portesis, N., Spanou, C., Mossialos, D., Aligiannis, N., Chaita, E., Panagoulis, C., Reri, E., Skaltsounis, L., Tsatsakis, A.M., Correlation of total polyphenolic content with antioxidant and antibacterial activity of 24 extracts from Greek domestic lamiaceae species. Food Chem. Toxicol. 50 (2012), 4115–4124.
105. Thomas, E., Gopalakrishnan, V., Hegde, M., Kumar, S., Karki, S.S., Raghavan, S.C., A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells. Sci. Rep., 2016, 2016, 6.
106. Venkatadri, R., Muni, T., Iyer, A., Yakisich, J., Azad, N., Role of apoptosis-related miRNAs in resveratrol-induced breast cancer cell death. Cell death Dis., 7, 2016, e2104.
107. Videira, M., Reis, R.L., Brito, M.A., Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochem. Biophys. Acta 1846 (2014), 312–325.
108. Yeo, C.Q.X., Alexander, I., Lin, Z., Lim, S., Aning, O.A., Kumar, R., Sangthongpitag, K., Pendharkar, V., Ho, V.H.B., Cheok, C.F., p53 maintains genomic stability by preventing interference between transcription and replication. Cell. Rep. 15 (2016), 132–146.
109. Zhao, E., Mu, Q., Phytoestrogen biological actions on Mammalian reproductive system and cancer growth. Sci. Pharm. 79 (2011), 1–20.
110. Zhang, P.-Y., Polyphenols in health and disease. Cell. biochem. Biophys. 73 (2015), 649–664.
111. Zhang, S., Cao, H.J., Davis, F.B., Tang, H.Y., Davis, P.J., Lin, H.Y., Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br. J. Cancer 91 (2004), 178–185.
112. Zheng, J., Ramirez, V.D., Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem. Biophys. Res. Commun. 261 (1999), 499–503.
113. Zuljevic, G., O'Brien, S., Phytoestrogens in Soy: a Tentative Protective Factor against Breast Cancer. 2016.